WELCOME TO
PSYCHEDELIC ALPHA
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Plus incubation, consultancy, and advisory for this emerging field.
Insights, Delivered
Join thousands of psychedelic insiders…
For in-depth analysis and insights, consider our paid offering…
Support
Consultancy, advisory and incubation offerings for investors, entrepreneurs, and beyond.
Our data and insights are cited in…
Pioneering the Future of Psychedelics
Psychedelic Alpha is your trusted resource for insights and updates on the rapidly evolving landscape of psychedelics. We provide open-access data, expert analysis, and the latest developments in policy reform, patent activity, and drug development. Our mission is to bridge the gap between research, industry, and public understanding, fostering a transparent and ethical approach to the resurgence of psychedelics in medicine, wellness, and beyond.
Our data and insights are cited in…
Open access data on psychedelic policy reform, patents, and drug development activity plays a crucial role in advancing the understanding and responsible use of psychedelics in modern medicine.
we support
Entrepreneurs and Startups
Whether you're at the idea-formation stage or raising early-stage funding, we're here to help across the entire psychedelic value chain and company life-cycle.
Investors and Corporates
We help investors and corporates of all stripes understand and support the psychedelics space: from syndicates and VCs through to institutions.
Psychedelic Insiders and the Curious
Join our newsletter to stay abreast of the rapidly emergent psychedelics industry: from clinical trials and patents through to healing centres and decriminalisation.
Trusted by 50,000+ businesses to scale outbound sales
Why Choose us
Limitless Creativity
Leo est sollicitudin metus eget mi eros curabitur tellus aptent a donec
Strategy-based Approach
Leo est sollicitudin metus eget mi eros curabitur tellus aptent a donec
Flexibility and Adaptability
Leo est sollicitudin metus eget mi eros curabitur tellus aptent a donec
Commitment to Quality
Leo est sollicitudin metus eget mi eros curabitur tellus aptent a donec
Impressive Outcomes
Leo est sollicitudin metus eget mi eros curabitur tellus aptent a donec
Clinical Trials
Clinical trials involving psychedelics started, per year
Phase 3 trials of MDMA-assisted therapy have been completed, with Phase 3 study of psilocybin underway.
On “Alpha”
‘Alpha’, in the investing world, refers to an excess return on investment relative to a benchmark. But we broaden the definition of alpha on both ends to include more than just economic returns on more than just economic investments.
Instead, we conceptualise alpha as the excess return on myriad investments that people may make in the present and future of psychedelics: beyond economic capital, people might invest time, energy, and effort, for example. And that excess return might not be (purely) financial, it might also be realised through a more impactful treatment paradigm for mental health, for example, where the ‘benchmark’ is the inadequate status quo.
All this to say, we’re not only for investors. In fact, most of our readers aren’t: many of them are practitioners, regulators, entrepreneurs, and so on.
Psychedelic Alpha
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Quick Links
Newsletter
Insights and interviews delivered to your inbox. No spam, just valuable information.
